Letters Section Editor: Robert M. Golub, MD, Senior Editor.
In Reply: In this study comparing the NMP22 point-of-care assay with cytology for detection of recurrent bladder cancer, both tests were compared with cystoscopy. Cystoscopy was performed in all patients at baseline and surveillance was performed according to the practice of the urologists participating in the study. All patients continued to have cystoscopic surveillance at various intervals, and follow-up cystoscopy data for all patients were reviewed for the first poststudy evaluation. Although cystoscopy is the standard for diagnosing bladder cancer, it is flawed and fails to detect some cancers.1 This makes the determination of false-positive tests more difficult.
Grossman HB. NMP22 and Surveillance for Recurrent Bladder Cancer—Reply. JAMA. 2006;296(1):44–46. doi:10.1001/jama.296.1.45-b